Mankind Pharma has confirmed the status of its share dematerialization and rematerialization requests for the final quarter of the fiscal year, covering the period from January 1, 2026, to March 31, 2026. The company has officially reported that it received zero requests for share dematerialization or rematerialization from its shareholders during this period.
Quarterly Share Processing Summary
In accordance with standard reporting procedures, Mankind Pharma has provided a formal update regarding its share registry activities for the fourth quarter (Q4: Jan-Mar) of the 2026 financial year. The company, in coordination with its Registrar and Share Transfer Agent, KFin Technologies Limited, has verified that no share dematerialization or rematerialization applications were received during the three-month window ending March 31, 2026.
Compliance and Registry Update
This disclosure confirms that the company maintained a consistent status regarding its physical and electronic share records throughout the quarter. As no requests were processed or pending during this time, the integrity of the shareholding records remains unchanged. This confirmation ensures that all stakeholders are updated on the share administration activities as of the quarter-end date of March 31, 2026.
Source: BSE
